Thermo Fisher Scientific, Agios Pharmaceuticals to Codevelop Glioma Companion Diagnostic
Thermo will develop a test using its Oncomine Precision Assay to identify IDH1- and IDH2-positive low-grade glioma patients for treatment with Agios' vorasidenib.
Memorial Sloan Kettering Using Cerebral Spinal Fluid Liquid Biopsy, Sequencing to Track Glioma Evolution
The researchers believe using cerebral spinal fluid will enable them to identify brain tumors with a higher sensitivity than with blood samples.
The researchers aim to offer the half-hour diagnostic assay for use during neurosurgery to help clinicians pursue the best treatment for patients with gliomas.
FDA Approves Abbott CDx, Agios Drug for AML Patients With IDH1 Mutation
This drug is the first FDA-approved IDH1 inhibitor and will be used to treat adult patients with relapsed or refractory acute myeloid leukemia.
Thermo Fisher, Agios Pharmaceuticals Strike CDx Partnership
The companies will work together on a next-generation sequencing-based companion diagnostic for Agios' investigational cancer drug ivosidenib.